Scholarlink

Background <p>Enhancer RNAs (eRNAs) are essential for cancer initiation and progression. However, the landscape of eRNAs and the clinical significance of eRNAs in colorectal cancer (CRC) liver metastases (CRLM) remain largely unknown.</p> Methods <p>We comprehensively profiled eRNAs in a CRLM cohort and delineated eRNA-based CRLM subtypes through unsupervised clustering of eRNAs and validated the subtyping framework in an external cohort. Molecular characteristics, immune infiltration, prognostic outcomes, and chemotherapy responses of the novel CRLM subtypes were further explored. Finally, we explored chemoresistance-related eRNAs and tentatively investigated the roles of eRNAs in CRC oxaliplatin resistance in vitro.</p> Results <p>Three novel eRNA-based CRLM subtypes, known as C1, C2, and C3, have been identified and validated in an external cohort. C1 has transcriptomic features of proliferative pathways. C2 is associated with the canonical primary CRC subtype. C3 is active in immune pathways and metabolic pathways. C2 has the highest chemotherapy response rate and has a better survival outcome than C1 and C3. In addition, we have revealed that knockdown of the eRNA (chr7:130571851–130572495) might influence oxaliplatin sensitivity in CRC cells.</p> Conclusions <p>Our findings unveil the molecular heterogeneity of CRLM through the lens of eRNAs and underscore the potential utility of eRNA in stratifying CRLM and guiding precision therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Enhancer RNAs profiling in colorectal cancer liver metastases reveals novel molecular subtypes with prognostic and therapeutic relevance

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月11日

查看全文
  • Xiaoyun Bu,
  • Dongsheng Wen,
  • Tiejun Zhou,
  • Lei Xiao,
  • Zhiqing Zhang,
  • Xingshuai Zhao,
  • Yingbin Hu

摘要

Background

Enhancer RNAs (eRNAs) are essential for cancer initiation and progression. However, the landscape of eRNAs and the clinical significance of eRNAs in colorectal cancer (CRC) liver metastases (CRLM) remain largely unknown.

Methods

We comprehensively profiled eRNAs in a CRLM cohort and delineated eRNA-based CRLM subtypes through unsupervised clustering of eRNAs and validated the subtyping framework in an external cohort. Molecular characteristics, immune infiltration, prognostic outcomes, and chemotherapy responses of the novel CRLM subtypes were further explored. Finally, we explored chemoresistance-related eRNAs and tentatively investigated the roles of eRNAs in CRC oxaliplatin resistance in vitro.

Results

Three novel eRNA-based CRLM subtypes, known as C1, C2, and C3, have been identified and validated in an external cohort. C1 has transcriptomic features of proliferative pathways. C2 is associated with the canonical primary CRC subtype. C3 is active in immune pathways and metabolic pathways. C2 has the highest chemotherapy response rate and has a better survival outcome than C1 and C3. In addition, we have revealed that knockdown of the eRNA (chr7:130571851–130572495) might influence oxaliplatin sensitivity in CRC cells.

Conclusions

Our findings unveil the molecular heterogeneity of CRLM through the lens of eRNAs and underscore the potential utility of eRNA in stratifying CRLM and guiding precision therapy.